uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026)

uniQure's (QURE) quarterly Net Income towards Common Stockholders came in at -$53.5 million in Q1 2026, down 22.68% year-on-year from -$69.2 million in Q1 2025, and down 425.48% quarter-over-quarter from $16.4 million in Q4 2025.

uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends

uniQure's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 22.68% year-over-year to -$53.5 million in Q1 2026; TTM through Mar 2026 was -$154.2 million, a 29.11% increase from a year earlier, with the FY2025 full-year figure at -$199.0 million, up 16.94% from the prior year.
  • Net Income towards Common Stockholders fell to -$53.5 million in Q1 2026 per QURE's latest filing, from $16.4 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $16.4 million in Q4 2025 and bottomed at -$89.6 million in Q3 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$53.5 million (2026), against an average of -$51.3 million.
  • Across the five-year window, Net Income towards Common Stockholders sank 1175.45% in 2023 and soared 122.45% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at $6.8 million in 2022, then sank by 1175.45% to -$73.2 million in 2023, then dropped by 0.08% to -$73.3 million in 2024, then soared by 122.45% to $16.4 million in 2025, then tumbled by 425.48% to -$53.5 million in 2026.
  • Per Business Quant, the three latest QURE Net Income towards Common Stockholders figures stand at -$53.5 million (Q1 2026), $16.4 million (Q4 2025), and -$79.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 uniQure 2.41 Bn 2.41 Bn 3.34 Mn -53.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -53.54 Mn
Dec 31, 2025 16.45 Mn
Sep 30, 2025 -79.42 Mn
Jun 30, 2025 -37.72 Mn
Mar 31, 2025 -43.64 Mn
Dec 31, 2024 -73.26 Mn
Sep 30, 2024 -44.38 Mn
Jun 30, 2024 -56.30 Mn
Mar 31, 2024 -65.62 Mn
Dec 31, 2023 -73.21 Mn
Sep 30, 2023 -89.57 Mn
Jun 30, 2023 -68.47 Mn
Mar 31, 2023 -77.23 Mn
Dec 31, 2022 6.81 Mn
Sep 30, 2022 -47.86 Mn
Jun 30, 2022 -39.06 Mn
Mar 31, 2022 -46.68 Mn
Dec 31, 2021 8.21 Mn
Sep 30, 2021 -36.53 Mn
Jun 30, 2021 399.47 Mn